Please use this identifier to cite or link to this item: https://doi.org/10.1002/ehf2.12228
Title: Chronic obstructive pulmonary disease and β-blocker treatment in Asian patients with heart failure
Authors: Kubota Y.
Tay W.T.
Asai K.
Murai K.
Nakajima I.
Hagiwara N.
Ikeda T.
Kurita T.
Teng T.-H.K.
Anand I.
Lam C.S.P. 
Shimizu W.
on behalf of the ASIA-HF Study investigators
Keywords: Chronic obstructive pulmonary disease
Heart failure
β-Blocker
Issue Date: 2018
Publisher: Wiley-Blackwell
Citation: Kubota Y., Tay W.T., Asai K., Murai K., Nakajima I., Hagiwara N., Ikeda T., Kurita T., Teng T.-H.K., Anand I., Lam C.S.P., Shimizu W., on behalf of the ASIA-HF Study investigators (2018). Chronic obstructive pulmonary disease and β-blocker treatment in Asian patients with heart failure. ESC Heart Failure 5 (2) : 297-305. ScholarBank@NUS Repository. https://doi.org/10.1002/ehf2.12228
Abstract: Aims: Chronic obstructive pulmonary disease (COPD) and heart failure (HF) are increasingly frequent in Asia and commonly coexist in patients. However, the prevalence of COPD among Asian patients with HF and its impact on HF treatment are unclear. Methods and results: We compared clinical characteristics and treatment approaches between patients with or without a history of COPD, before and after 1:2 propensity matching (for age, sex, geographical region, income level, and ethnic group) in 5232 prospectively recruited patients with HF and reduced ejection fraction (HFrEF, <40%) from 11 Asian regions (Northeast Asia: South Korea, Japan, Taiwan, Hong Kong, and China; South Asia: India; Southeast Asia: Thailand, Malaysia, Philippines, Indonesia, and Singapore). Among the 5232 patients with HFrEF, a history of COPD was present in 8.3% (n = 434), with significant variation in geography (11.0% in Northeast Asia vs. 4.7% in South Asia), regional income level (9.7% in high income vs. 5.8% in low income), and ethnicity (17.0% in Filipinos vs. 5.2% in Indians) (all P < 0.05). Use of mineralocorticoid receptor antagonists and diuretics was similar between groups, while usage of all β-blockers was lower in the COPD group than in the non-COPD group in the overall (66.3% vs. 79.9%) and propensity-matched cohorts (66.3% vs. 81.7%) (all P < 0.05). A striking exception was the Japanese cohort in which β-blocker use was high in COPD and non-COPD patients (95.2% vs. 91.2%). Conclusions: The prevalence of COPD in HFrEF varied across Asia and was related to underuse of β-blockers, except in Japan. © 2017 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of the European Society of Cardiology.
Source Title: ESC Heart Failure
URI: http://scholarbank.nus.edu.sg/handle/10635/152051
ISSN: 20555822
DOI: 10.1002/ehf2.12228
Appears in Collections:Elements
Staff Publications

Show full item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
ehf2.12228.pdf135.2 kBAdobe PDF

OPEN

NoneView/Download

Page view(s)

18
checked on Jun 13, 2019

Download(s)

2
checked on Jun 13, 2019

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.